Investors got it all wrong when this medical technology blue chip reported results in February. A selloff ensued, which Taesik Yoon, editor of Forbes Investor, says lacks any real merit. This is good news, because now Wall Street has set the state for us to profit from this company's strong rebound.
In this free report, The One Stock to Buy In April, you'll find out the name of the company that's reaping the rewards of its recent acquisition of a competitor and seeing revenues jump 42.2%.
So enter your email address below to get the full profile of the $3.2 billion blue chip you've probably never heard of.